Highlights a couple of takeover, acquisitions or collaboration of Australian biotechs by giant foreign pharmaceuticals. Notable ones include Acrux, Chemgenex, Mesoblast, Biota and Cellestis.
Life-science battlers have a spring in their step
This article talks about a few small caps funds and the fact that it is getting harder to choose a winning small cap. Also provides a historical view of small caps that have become huge successes, like Cochlear, Super Cheap Auto and The Reject Shop.
Small-caps scarce but worth wait: a lack of floats has tightened the market
Highlights a few highly speculative mining stocks. Miners include those with Australian as well as foreign operations, like in Africa.
Mining stocks flying under the radar
Introduces a new rare earths company called Data Motion, which used to be an IT company.
Rare earths worth a shot for IT minnow
Finally an article on ETF which has gained worldwide popularity among investors. This article however, cautions about ETFs. In particular synthetic ETFs carry much more risk since they are based on derivative and leveraged products, rather than just mirroring the index.
Exchange traded funds under global scrutiny
Posts
